thiothixene has been researched along with Basal Ganglia Diseases in 13 studies
Thiothixene: A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 5.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| " It is suggested that additional studies, carefully designed, on dosage and plasma levels could help in achieving the lowest possible therapeutic dosage and thus in minimizing side effects." | 2.37 | Blood levels of neuroleptics: state of the art. ( Simpson, GM; Yadalam, K, 1985) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 1.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (92.31) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weinberg, S | 1 |
| Twersky, RS | 1 |
| Van Putten, T | 2 |
| May, PR | 2 |
| Marder, SR | 2 |
| Tune, LE | 1 |
| McHugh, PR | 1 |
| Coyle, JT | 1 |
| Wittmann, LA | 1 |
| Lavin, MR | 1 |
| Mason, AS | 1 |
| Granacher, RP | 1 |
| Eisdorfer, C | 1 |
| Swett, C | 1 |
| Rosse, RB | 1 |
| Theut, SK | 1 |
| Banay-Schwartz, M | 1 |
| Leighton, M | 1 |
| Scarcella, E | 1 |
| Cohen, CG | 1 |
| Deutsch, SI | 1 |
| Simpson, GM | 2 |
| Yadalam, K | 1 |
| Charalampous, KD | 1 |
| Freemesser, GF | 1 |
| Malev, J | 1 |
| Ford, K | 1 |
| Lee, JH | 1 |
| Branchey, M | 1 |
| Haher, EJ | 1 |
| Varga, E | 1 |
| Ban, TA | 1 |
| Lehmann, HE | 1 |
1 review available for thiothixene and Basal Ganglia Diseases
| Article | Year |
|---|---|
Blood levels of neuroleptics: state of the art.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Drug | 1985 |
2 trials available for thiothixene and Basal Ganglia Diseases
| Article | Year |
|---|---|
Loxapine succinate: a controlled double-blind study in schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Basal Ganglia Diseases; Clinical Trials as Topic; Dibenzoxa | 1974 |
Once versus thrice daily thiothixene in the treatment of schizophrenic in-patients.
Topics: Basal Ganglia Diseases; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Placebos; Psych | 1974 |
10 other studies available for thiothixene and Basal Ganglia Diseases
| Article | Year |
|---|---|
Neuroleptic malignant syndrome.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Female; Fever; Humans; Muscles; Nervous System | 1983 |
Response to antipsychotic medication: the doctor's and the consumer's view.
Topics: Adult; Akathisia, Drug-Induced; Attitude of Health Personnel; Attitude to Health; Basal Ganglia Dise | 1984 |
Management of extrapyramidal side effects induced by neuroleptics.
Topics: Adult; Basal Ganglia Diseases; Benztropine; Humans; Male; Parasympatholytics; Receptors, Dopamine; R | 1981 |
Subjective response to antipsychotic drugs.
Topics: Affective Symptoms; Basal Ganglia Diseases; Emotions; Humans; Patient Compliance; Psychiatric Status | 1981 |
Neuroleptic-induced extrapyramidal side effects.
Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Drug Therapy, Combination; Eye Movements; Female; H | 1993 |
Basic principles of rapid neuroleptization.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Fluphenazine; Ha | 1976 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Basal Ganglia Diseases; Benztropine; Chronic Disease; Cognitio | 1989 |
Thiothixene and the thioxanthenes.
Topics: Basal Ganglia Diseases; Dementia; Depression; Drug Synergism; Female; Humans; Male; Mental Disorders | 1974 |